跳至主要内容
临床试验/NCT02396381
NCT02396381已完成不适用

A Randomized, Controlled, 2-arm Parallel Group, Multi-center Study, to Evaluate Biological and Functional Changes in Healthy Smokers Switching to Tobacco Heating System 2.2 (THS 2.2) Compared to Continuing Smoking Conventional Cigarettes for 26 Weeks in an Ambulatory Setting

Philip Morris Products S.A.19 个研究点 分布在 1 个国家目标入组 1,039 人开始时间: 2015年3月12日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
1,039
试验地点
19
主要终点
Concentrations of 8-epi-prostaglandin F2α (8-epi-PGF2α).

研究概览

简要总结

The aim of the study is to demonstrate clinical, biological and functional health changes in smokers switching to the candidate modified risk tobacco product: Tobacco Heating System 2.2 (THS 2.2) as compared to smokers continuing smoking their conventional cigarettes (CC) over a 26-week period.

To characterize the study as successful, at least 5 clinical risk endpoints should move in the direction of smoking cessation and these results would be statistically significant. The main analysis will be defined a priori (using the Hailperin-Ruger approach) and will be made between THS 2.2 use and CC use as "per actual product used" and product use categories.

详细描述

The clinical, biological and functional endpoints to be measured in this study ("smoker's health profile") may characterize the modification of risk of smoking-related diseases.

Clinical risk endpoint to be assessed are selected based on a) their association to smoking-related diseases b) their association to smoking status, c) their reversibility upon smoking cessation, and d) their suitability to be measured with valid and robust methods in clinical studies.

The biological markers, functional markers and biomarkers of exposure (BoExp) with the strongest scientific evidence will constitute the 'smoker's health profile' and will be measured as the primary objective of the study.

Additional endpoints involved in the mechanistic of smoking-related diseases will be studied to provide additional scientific evidence to strengthen the primary objective.

The study will provide a perspective of product usage in a "real world setting" where smoking CC in addition to THS 2.2 may be expected.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
30 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Current healthy smoker as judged by the Principal Investigator(s) or designee(s)
  • •Minimum age: 30 years old
  • •Have smoked for the last 10 years
  • •Have smoked more than 10 non menthol CC/day on average (no brand restriction) over the past year

排除标准

  • •Clinically relevant medical conditions that in the opinion of the investigators would jeopardize the safety of the participant.
  • •Subject who has (FEV1/FVC) < 0.7 and FEV1 < 80% predicted value at post-bronchodilator spirometry
  • •Subject with asthma condition (post-bronchodilator FEV1/FVC < 0.75 and reversibility in FEV1 ≥ 12% and > 200 mL from pre- to post-bronchodilator values)
  • •Subject who took or is taking concomitant medication which may have an impact on the "smoker's heath profile"
  • •Female subject is pregnant or breast feeding.
  • •Female subject who does not agree to use an acceptable method of effective contraception.

研究组 & 干预措施

THS 2.2

Experimental

Ad libitum use of THS 2.2

干预措施: THS 2.2 (Other)

CC

Active Comparator

Ad libitum use of CC

干预措施: CC (Other)

结局指标

主要结局

Concentrations of 8-epi-prostaglandin F2α (8-epi-PGF2α).

时间窗: 26 Weeks

Concentrations measured in urine and expressed as concentration adjusted for creatinine. Geometric Least Squares means are provided as descriptive statistics.

Levels of High Density Lipoprotein C (HDL-C).

时间窗: 26 Weeks

Concentrations measured in serum. Geometric Least Squares means are provided as descriptive statistics.

Levels of White Blood Cells (WBC).

时间窗: 26 Weeks

Concentrations measured in blood. Geometric Least Squares means are provided as descriptive statistics.

Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1).

时间窗: 26 Weeks

FEV1 post-bronchodilator and expressed as percentage predicted (FEV1 %pred). Geometric Least Squares means are provided as descriptive statistics.

Concentrations of Soluble Intercellular Adhesion Molecule 1 (sICAM-1).

时间窗: 26 Weeks

Concentrations measured in serum. Geometric Least Squares means are provided as descriptive statistics.

Concentrations of 11-dehydrothromboxane B2 (11-DTXB2).

时间窗: 26 Weeks

Concentrations measured in urine and expressed as concentration adjusted for creatinine. Geometric Least Squares means are provided as descriptive statistics.

Concentrations of Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL).

时间窗: 26 Weeks

Concentrations measured in urine and expressed as concentration adjusted for creatinine. Geometric Least Squares means are provided as descriptive statistics.

Percent Change From Baseline of Carboxyhemoglobin (COHb)

时间窗: 26 Weeks

Carboxyhemoglobin (COHb) is assayed from whole blood. Geometric Least Squares means are provided as descriptive statistics. Expressed as % of saturation of hemoglobin.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (19)

Loading locations...

相似试验